Grace Therapeutics, a late-stage biopharma company developing GTx-104 for aneurysmal Subarachnoid Hemorrhage (aSAH), announced participation in key industry and investor conferences in November 2026, including BIO-Europe in Germany and the Craig-Hallum Alpha Select Conference in New York. CEO Prashant Kohli will engage with industry leaders and investors to discuss the company’s novel injectable nimodipine formulation, which has FDA Orphan Drug Designation and aims to improve treatment for aSAH patients. These events provide opportunities to advance partnerships and update stakeholders on regulatory progress and clinical development milestones for GTx-104.
Grace Therapeutics' upcoming participation in industry events is presented here with a snapshot of the health sector on Pluang as of Nov 05, 2026 19:01 WIB. Out of 150 priced health-sector US stocks, 94 rose and 48 fell today. Notable movers include Oscar Health Inc (OSCR) at USD 36.95 with a 5.00% gain and Adaptive Biotechnologies Corp (ADPT) at USD 27.99 with a 4.79% gain, while Alumis Inc (ALMS) dropped 5.34% to USD 6.20.
Global tech giants like Amazon, Google, and Microsoft are committing hundreds of billions of dollars to expand AI-focused data center accelerators, driven by surging demand from generative AI workloads that exceed traditional CPU capabilities. These ...
Berkshire Hathaway's stock portfolio is now worth about three times what the company originally paid for it. These gains alone represent roughly 19% of Berkshire Hathaway's total company value, highlighting the significant growth and value generated ...
C3is Inc. will implement a one-for-five reverse stock split effective November 9, 2026, reducing its outstanding shares from about 4.2 million to 0.84 million. This move aims to increase the stock price to meet Nasdaq's minimum bid price requirement ...
Firmly secured $15 million in a Series A funding round led by Squarepoint Capital, with participation from J.P. Morgan Payments, Mastercard, and Samsung NEXT. The company provides a no-code platform that connects merchants to AI-driven shopping chann...
On November 4, 2026, Shell plc repurchased a total of 1,876,276 shares across multiple trading venues including LSE, Chi-X, BATS, XAMS, CBOE, and TQEX. The shares were bought at prices ranging from £37.98 to £38.82 and €45.70 to €46.72, with an avera...
